IonQ, Inc. — Q3 2021 Form 10-Q
Business context and period: Covers the three and nine months ended September 30, 2021. IonQ develops trapped-ion quantum computers and sells access through quantum-computing-as-a-service (QCaaS) and related services. On September 30, the company completed its business combination with dMY Technology Group III and began trading as IONQ. The transaction is accounted for as a reverse recapitalization, so prior-period results reflect Legacy IonQ.
Financial results and position
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Revenue | $0.233 million | $0 | $0.451 million | $0 |
| Operating costs and expenses | $10.757 million | $3.576 million | $28.301 million | $10.798 million |
| Operating loss | $10.524 million | $3.576 million | $27.850 million | $10.798 million |
| Net loss | $14.781 million | $3.565 million | $32.102 million | $10.493 million |
| Loss per share, basic and diluted | $0.12 | $0.03 | $0.27 | $0.09 |
Margins: Q3 cost of revenue, excluding depreciation and amortization, was $0.234 million against $0.233 million of revenue, implying slightly negative gross profit on that basis. The filing does not provide a clear reported gross-margin figure.
Cash flow and liquidity: At September 30, cash and cash equivalents were $587.294 million, versus $36.120 million at December 31, 2020; current assets were $597.854 million and current liabilities $11.076 million. For the first nine months, operating cash use was $21.851 million, investing cash use $6.914 million, and financing cash inflow $579.939 million. Financing included $575.483 million net proceeds from the merger and PIPE. Management said cash on hand should fund working capital and capital expenditures for at least the next 12 months.
Capital structure and other metrics: Total liabilities were $68.892 million, including $50.350 million of warrant liabilities and $4.245 million of operating lease liabilities; the filing reports no borrowings or debt balance. Stockholders’ equity was $557.667 million and accumulated deficit $71.707 million. Common shares outstanding at September 30 were 190.197 million; 192.487 million were reported outstanding as of November 8. The merger and PIPE generated approximately $636 million gross proceeds, including $345 million from the PIPE, and involved issuance of 70.303 million common shares net of transaction costs in the equity statement.
Material changes versus prior comparable periods
- Revenue began to be recognized in 2021: $0.233 million in Q3 and $0.451 million for nine months, primarily from new customer contracts. The comparable 2020 periods had no revenue.
- Operating expenses rose substantially as IonQ expanded research and development, staffing, sales and marketing, and public-company functions. Nine-month R&D increased to $15.311 million from $7.643 million; G&A to $8.321 million from $1.840 million.
- Nine-month net loss widened to $32.102 million from $10.493 million. Q3 2021 includes $4.259 million of warrant-related offering costs associated with the business combination.
- Cash increased markedly following the September 30 merger and PIPE. The company also recorded $50.350 million of warrant liabilities at closing.
Outlook, commentary, risks and unusual items
- Management expects significant losses to continue as IonQ invests in research, development, commercialization and public-company requirements. The filing says significant production is not expected before 2025 at the earliest, and may occur later or never. No specific revenue or earnings guidance is provided.
- Remaining performance obligations on non-cancelable contracts were approximately $15.9 million at September 30; IonQ expected to recognize $1.1 million in the remainder of 2021 and $4.5 million in 2022, with the remainder thereafter. Timing for usage-based obligations was not estimated.
- IonQ reported an 11-algorithmic-qubit system available to customers; its next-generation system was under development and not yet available. Management cited technical and manufacturing challenges to scaling, achieving fidelity and broad quantum advantage, as well as competition, supplier constraints and dependence on cloud providers.
- Risks include the early-stage market and limited operating history, continued losses, reliance on key talent and university intellectual-property licenses, customer and cloud-provider concentration, COVID-19 and supply-chain disruption, cybersecurity, and possible future financing needs. Revenue came from two significant customers in Q3 and three in the nine-month period. A September 2021 UMD agreement provides $14 million for quantum-computing services and facility access; $3.836 million of related unearned revenue was recorded at quarter-end.
- Disclosure controls were judged ineffective because a material weakness in financial reporting controls continued: insufficient experienced accounting staff and segregation of duties, and limited financial-system controls. Remediation efforts include hiring qualified personnel and upgrading systems; remediation was not yet complete.
- The filing describes a lawsuit in which dMY and related parties, and now the company, are counterclaim defendants. The claims were denied and a motion to dismiss was filed. Management stated it knew of no pending claims or actions expected to have a material adverse effect.
- The business combination was accounted for as a reverse recapitalization, not an acquisition; no goodwill was recorded. The Q3 results include Legacy IonQ’s historical operations and dMY only after the September 30 closing.
Most important facts for investors to verify
- Whether IonQ can convert its small initial revenue base and $15.9 million of disclosed remaining obligations into sustained commercial growth.
- Whether cash use, hiring and capital investment remain consistent with management’s stated minimum 12-month liquidity outlook.
- Progress and independent validation of the technical roadmap, including next-generation systems, scalability, fidelity and the timing of commercial production.
- Customer and cloud-provider concentration, the terms and execution of the UMD agreement, and the status and economics of university IP licenses.
- Remediation and testing of the material weakness, including whether disclosure controls become effective.
- Potential dilution from outstanding warrants, options and equity plans; warrant valuation is sensitive to assumptions and share-price changes.
- Developments in the disclosed litigation, COVID-19 and supply-chain exposure, and any changes in financing requirements or formal guidance.